[
  {
    "title": "睿昂基因(688217.SH)：减持期已过半、辰贺投资尚未减持公司股份",
    "href": "http://stock.jrj.com.cn/2022/12/21153737228273.shtml",
    "datetime": "2022-12-21 15:37:53",
    "code": "688217"
  },
  {
    "title": "A股异动 | 睿昂基因跌超4% 第二大股东拟减持不超6%股份",
    "href": "http://stock.jrj.com.cn/2022/12/19101937221664.shtml",
    "datetime": "2022-12-19 10:19:35",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：浙江大健康拟减持不超6%股份",
    "href": "http://stock.jrj.com.cn/2022/12/16183037218962.shtml",
    "datetime": "2022-12-16 18:30:32",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：拟发行可转债募资不超4.5亿元 用于分子诊断试剂产业化建设项目等",
    "href": "http://stock.jrj.com.cn/2022/11/30173737178626.shtml",
    "datetime": "2022-11-30 17:37:03",
    "code": "688217"
  },
  {
    "title": "助力结直肠癌精准诊疗 睿昂基因出席默克“规范化结直肠癌精准检测之路”启动仪式",
    "href": "http://stock.jrj.com.cn/2022/11/28083937169801.shtml",
    "datetime": "2022-11-28 08:39:13",
    "code": "688217"
  },
  {
    "title": "睿昂基因携手国润医疗 共推肿瘤基因检测覆盖",
    "href": "http://stock.jrj.com.cn/2022/11/16111137142988.shtml",
    "datetime": "2022-11-16 11:11:09",
    "code": "688217"
  },
  {
    "title": "睿昂基因与阿斯利康签署战略合作协议 共推“肺癌罕见突变生态圈”发展",
    "href": "http://stock.jrj.com.cn/2022/11/07083237115866.shtml",
    "datetime": "2022-11-07 08:32:15",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：辰德投资完成清仓减持1.7%股份",
    "href": "http://stock.jrj.com.cn/2022/11/02170437106930.shtml",
    "datetime": "2022-11-02 17:04:59",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：睿泓投资及重庆睿安拟合计减持不超7.26%股份",
    "href": "http://stock.jrj.com.cn/2022/11/02170237106934.shtml",
    "datetime": "2022-11-02 17:02:56",
    "code": "688217"
  },
  {
    "title": "睿昂基因：第三季度扣非净利润增近两成 大力推动新产品开发入院工作",
    "href": "http://stock.jrj.com.cn/2022/10/27085437088410.shtml",
    "datetime": "2022-10-27 08:54:43",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：第三季度净利降13.86%至1533.89万元",
    "href": "http://stock.jrj.com.cn/2022/10/26195637086993.shtml",
    "datetime": "2022-10-26 19:56:51",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：辰贺投资拟减持不超过2.91%股份",
    "href": "http://stock.jrj.com.cn/2022/08/30010536949982.shtml",
    "datetime": "2022-08-30 01:05:14",
    "code": "688217"
  },
  {
    "title": "睿昂基因：辰贺投资拟减持不超过2.91%股份",
    "href": "http://stock.jrj.com.cn/2022/08/29160036947238.shtml",
    "datetime": "2022-08-29 16:00:01",
    "code": "688217"
  },
  {
    "title": "睿昂基因半年报：营收同比增长26.98% 多元化布局打开成长空间",
    "href": "http://stock.jrj.com.cn/2022/08/25162936935906.shtml",
    "datetime": "2022-08-25 16:29:00",
    "code": "688217"
  },
  {
    "title": "睿昂基因披露2022年半年报 实现营收1.73亿元",
    "href": "http://stock.jrj.com.cn/2022/08/25091936934015.shtml",
    "datetime": "2022-08-25 09:19:15",
    "code": "688217"
  },
  {
    "title": "研报评睿昂基因：多元化布局打开成长空间 预计将呈现加速增长趋势",
    "href": "http://stock.jrj.com.cn/2022/07/28094136849439.shtml",
    "datetime": "2022-07-28 09:41:01",
    "code": "688217"
  },
  {
    "title": "睿昂基因携手诺诚健华 构建更完善的淋巴瘤基因检测体系",
    "href": "http://stock.jrj.com.cn/2022/07/04173536780513.shtml",
    "datetime": "2022-07-04 17:35:20",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：拟使用不超1.3亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/06/28210836765854.shtml",
    "datetime": "2022-06-28 21:08:08",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217)：股东减持股份计划",
    "href": "http://stock.jrj.com.cn/2022/05/25084236676201.shtml",
    "datetime": "2022-05-25 08:42:04",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：辰德投资拟减持不超1.70%股份",
    "href": "http://stock.jrj.com.cn/2022/05/24154136674112.shtml",
    "datetime": "2022-05-24 15:41:13",
    "code": "688217"
  },
  {
    "title": "睿昂基因2022年第一季度亏损233.12万 仪器、人员等固定成本增加",
    "href": "http://stock.jrj.com.cn/2022/05/03183236545985.shtml",
    "datetime": "2022-05-03 18:32:45",
    "code": "688217"
  },
  {
    "title": "睿昂基因多条业务线进入快速增长期 打造肿瘤精准检测龙头",
    "href": "http://stock.jrj.com.cn/2022/04/20202436412613.shtml",
    "datetime": "2022-04-20 20:24:45",
    "code": "688217"
  },
  {
    "title": "睿昂基因2021年净利4733.26万同比增长22.26% 董事长熊慧薪酬39.6万",
    "href": "http://stock.jrj.com.cn/2022/04/20145336409279.shtml",
    "datetime": "2022-04-20 14:53:50",
    "code": "688217"
  },
  {
    "title": "睿昂基因披露2021年年报 实现营收2.91亿元",
    "href": "http://stock.jrj.com.cn/2022/04/20090436406793.shtml",
    "datetime": "2022-04-20 09:04:22",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：2021年度净利升22.26%至4733.26万元",
    "href": "http://stock.jrj.com.cn/2022/04/20085436406419.shtml",
    "datetime": "2022-04-20 08:54:17",
    "code": "688217"
  },
  {
    "title": "睿昂基因再启核酸检测业务 “人停检测机器不停”助力上海抗疫",
    "href": "http://stock.jrj.com.cn/2022/04/12152536321747.shtml",
    "datetime": "2022-04-12 15:25:23",
    "code": "688217"
  },
  {
    "title": "睿昂基因：白血病相关15种融合基因检测试剂盒获批上市 继续强势领跑白血病分子诊断行业",
    "href": "http://stock.jrj.com.cn/2022/03/11201634815682.shtml",
    "datetime": "2022-03-11 20:16:37",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：子公司白血病相关15种融合基因检测试剂盒(荧光RT-PCR法)获得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/11190034815134.shtml",
    "datetime": "2022-03-11 19:00:36",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：拟推2022年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2022/03/11185434815118.shtml",
    "datetime": "2022-03-11 18:54:15",
    "code": "688217"
  },
  {
    "title": "睿昂基因2021年净利4601.31万同比增长18.86% 核心产品和服务增长",
    "href": "http://stock.jrj.com.cn/2022/02/25183034465426.shtml",
    "datetime": "2022-02-25 18:30:32",
    "code": "688217"
  },
  {
    "title": "睿昂基因董事会、监事会换届选举及聘任高级管理人员 第三季度公司净利1780.72万",
    "href": "http://stock.jrj.com.cn/2021/12/07185333981064.shtml",
    "datetime": "2021-12-07 18:53:08",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：51.04万股限售股将于11月17日解禁上市",
    "href": "http://stock.jrj.com.cn/2021/11/09183533828485.shtml",
    "datetime": "2021-11-09 18:35:08",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：第三季度净利润升21.64%至1780.72万元",
    "href": "http://stock.jrj.com.cn/2021/10/26155733754547.shtml",
    "datetime": "2021-10-26 15:57:36",
    "code": "688217"
  },
  {
    "title": "睿昂基因2021年半年度净利2492.91万元 同比净利增加81.64%",
    "href": "http://stock.jrj.com.cn/2021/08/26185933325828.shtml",
    "datetime": "2021-08-26 18:59:15",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：上半年净利增81.64%至2492.91万元",
    "href": "http://stock.jrj.com.cn/2021/08/26174433325195.shtml",
    "datetime": "2021-08-26 17:44:58",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)及子公司累计获得政府补助732.02万元",
    "href": "http://stock.jrj.com.cn/2021/08/13180233249732.shtml",
    "datetime": "2021-08-13 18:02:29",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：控股孙公司思泰得获得医疗机构执业许可证",
    "href": "http://stock.jrj.com.cn/2021/08/04154033201090.shtml",
    "datetime": "2021-08-04 15:40:15",
    "code": "688217"
  },
  {
    "title": "A股异动 | 睿昂基因(688217.SH)涨近7% 与大塚制药就白血病基因检测产品签署独家经销协议",
    "href": "http://stock.jrj.com.cn/2021/07/02143233033362.shtml",
    "datetime": "2021-07-02 14:32:02",
    "code": "688217"
  },
  {
    "title": "睿昂基因：与大塚制药签署《独家经销协议》 对公司市场化布局将起到积极作用",
    "href": "http://stock.jrj.com.cn/2021/07/01195333029042.shtml",
    "datetime": "2021-07-01 19:53:02",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：就白血病基因检测产品WT1 mRNA测定试剂盒与大塚制药签署独家经销协议",
    "href": "http://stock.jrj.com.cn/2021/07/01171533028017.shtml",
    "datetime": "2021-07-01 17:15:04",
    "code": "688217"
  },
  {
    "title": "睿昂基因：公司目前暂无德尔塔的相关研发",
    "href": "http://stock.jrj.com.cn/2021/06/24130832988925.shtml",
    "datetime": "2021-06-24 13:08:07",
    "code": "688217"
  },
  {
    "title": "睿昂基因：公司曾于2020年研发相关新冠肺炎病毒检测试剂盒",
    "href": "http://stock.jrj.com.cn/2021/05/27112132828377.shtml",
    "datetime": "2021-05-27 11:21:36",
    "code": "688217"
  },
  {
    "title": "今日上市：睿昂基因、亚辉龙",
    "href": "http://stock.jrj.com.cn/2021/05/17090332767395.shtml",
    "datetime": "2021-05-17 09:03:00",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217)：将于5月17日在上海证券交易所科创板上市",
    "href": "http://stock.jrj.com.cn/2021/05/14100732753884.shtml",
    "datetime": "2021-05-14 10:07:49",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：公司股票将于5月17日起上市交易",
    "href": "http://stock.jrj.com.cn/2021/05/13200132750206.shtml",
    "datetime": "2021-05-13 20:01:48",
    "code": "688217"
  },
  {
    "title": "【兑奖啦】科创板睿昂基因网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2021/05/06191332702817.shtml",
    "datetime": "2021-05-06 19:13:15",
    "code": "688217"
  },
  {
    "title": "睿昂基因(688217.SH)：网上发行最终中签率为0.02683520%",
    "href": "http://stock.jrj.com.cn/2021/05/05205932682445.shtml",
    "datetime": "2021-05-05 20:59:15",
    "code": "688217"
  },
  {
    "title": "睿昂基因4月30日申购：发行市盈率30倍",
    "href": "http://stock.jrj.com.cn/2021/04/29200032481952.shtml",
    "datetime": "2021-04-29 20:00:54",
    "code": "688217"
  },
  {
    "title": "力源环保、睿昂基因、博众精工、和辉光电科创板IPO注册生效",
    "href": "http://stock.jrj.com.cn/2021/04/08174232333058.shtml",
    "datetime": "2021-04-08 17:42:13",
    "code": "688217"
  },
  {
    "title": "力源环保、睿昂基因、博众精工科创板IPO进入“提交注册”阶段",
    "href": "http://stock.jrj.com.cn/2021/04/08100332330491.shtml",
    "datetime": "2021-04-08 10:03:30",
    "code": "688217"
  },
  {
    "title": "和辉光电、睿昂基因、品高软件科创板IPO提交注册",
    "href": "http://stock.jrj.com.cn/2021/04/07100432323189.shtml",
    "datetime": "2021-04-07 10:04:30",
    "code": "688217"
  },
  {
    "title": "证监会同意博众精工、睿昂基因、力源环保、和辉光电科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/04/06210432320832.shtml",
    "datetime": "2021-04-06 21:04:00",
    "code": "688217"
  },
  {
    "title": "睿昂基因：今年科创板过会第185家 海通证券过18.5单",
    "href": "http://stock.jrj.com.cn/2020/11/27113131359013.shtml",
    "datetime": "2020-11-27 11:31:00",
    "code": "688217"
  },
  {
    "title": "睿昂基因拟募资超总资产 产品价降上半年应收款超营收",
    "href": "http://stock.jrj.com.cn/2020/11/24070631334872.shtml",
    "datetime": "2020-11-24 07:06:00",
    "code": "688217"
  },
  {
    "title": "兴嘉生物、睿昂基因将于11月26日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2020/11/17215031302380.shtml",
    "datetime": "2020-11-17 21:50:00",
    "code": "688217"
  },
  {
    "title": "研发费用率较高但净现比不及同行 生物科技“独角兽”睿昂基因冲刺科创板IPO | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/10/16162831068098.shtml",
    "datetime": "2020-10-16 16:28:03",
    "code": "688217"
  }
]